Cracking the microbiome-cancer connection: Meet Wadie D. Mahauad-Fernandez, PhD, postdoctoral oncological research fellow

WDMF1

The cutting edge of cancer research is finding connections between tumor growth and the composition of gut microbiomes. Wadie D. Mahauad-Fernandez, Ph.D., is a postdoctoral oncology fellow at Stanford University, in Stanford, Calif. He and his team are exploring how delicate interplay of chemicals produced by gut flora impact cancer and vice versa.


How did you first get interested in science and microbiome research?

I started to be interested in science when I was a kid. I used to have a small microscope toy and I remember picking up dirt and small insects to look at them. Then, in high school I leaned towards Biology as I loved the complexity but also the beauty of how things in our body work. My passion for microbiome research started as an undergraduate student, at Augustana University (SD), studying the symbiotic relationships of oral bacteria. In graduate school at The University of Iowa, on top of my research on the role of an antiviral factor in breast cancer, I had the privilege of working in several virology research projects and served as a teaching assistant for undergraduate microbiology classes. Nowadays at Stanford University, I’m thankful to be able to go back to microbiome research to evaluate the role of the gut microbiota in cancer development.

Can you tell us a little about your project?

My proposal entailed comprehensively mapping the molecular signaling networks between the gut microbiota and cancer cell pathways that affect growth and survival of oncogene-addicted tumors. In other words, we are defining the role of the gut microbiota in the growth of oncogene-addicted cancers.

This is based on data showing that microbiome ablation results in impaired tumor growth of oncogene-addicted cancers due to changes in autonomous pathways. I proposed 1) to identify bacterial species that play a causal role in regulating the expression of genes involved in cancer cell growth; 2) to analyze changes in bacterial gene expression that result from tumor growth; 3) to identify cancer-driving genes altered by microbiome depletion; and 4) to perform computational analyses to identify gut microbial species associated with transcriptional changes of key genes involved in tumor growth.

WDMF2

What happens on a typical day for you in the lab?

I start my day with in vitro experiments in the tissue culture hood, then my day continues with in vivo experiments in mice and with wet bench experiments. At the end of the day, I focus my time on data analysis and generation of new experimental ideas. These activities are complemented by several meetings with other fellows and collaborators, training and mentoring undergraduate students, and writing manuscripts and grant proposals.

WDMF3

What do you find most interesting about your project? What is the most interesting or surprising result you have found?

I was very intrigued by the fact that changes in gut microbiota composition can alter cancer cell autonomous pathways. In a more general way, I find interesting the idea that we can alter the gut microbiota to better treat and diagnose cancers in a potentially less invasive way than current approaches. Just like immunotherapy where, in some cases, we exploit our own immune system to attack the cancer. I foresee that harnessing the functions of the gut microbiota will be of therapeutic benefit against cancer. I find it remarkable how we can change the outcome of a complex disease such as cancer by modifying bacterial populations in our gastrointestinal tract.

What kind of microbiome research do you perform and how does it impact health and disease or the environment? Where do you see this heading in the next five years?

I focus on cancer research and my goal is to define the role of the gut microbiota in the growth of oncogene addicted cancers. Understanding the role of the microbiome in cancer can result in the development of better therapeutic strategies, non-invasive diagnostic tools, and in the development of adjuvant factors that can be used to enhance current anti-cancer treatments.

I foresee my research resulting in the identification of specific bacteria species and specific metabolites that affect cancer cell intrinsic pathways. I believe that we can harvest the functions of the gut microbiota therapeutically to treat cancers for which treatments are limited or nonexistent.

WDMF4

What are your hobbies?

Outside the lab I enjoy barbequing, hiking around the northern California area, going out with friends, as well as playing sports including soccer and basketball. I am a big sports fan, so a good portion of my time is devoted to watching football, soccer, and basketball games. Pretty much any sport that is played with a ball (except baseball).

What are the major challenges you face in your research with regards to sample collection, nucleic acid isolation and data analysis?

One of our major challenge is scalability. To have the ability to process and analyze several samples at a time. Another challenge that we face is using newer software and programs to be able to put together large amounts of data in one network to identify new associations between control and treated groups; In my case, to find associations between specific bacterial species and cancer outcomes. Therefore, fostering new collaborations becomes vital in our turf where we are experts in a specific field but cannot succeed unless we complement our knowledge with that of scientists in other fields of study.

Which MO BIO or QIAGEN products do you use/have you used in the past and what did you like about the products?

We routinely use several kits from QIAGEN (DNeasy PowerSoil Pro Kit, DNeasy PowerSoil Pro QIAcube HT Kit) for the isolation of RNA and DNA from cells, tissues, and stool samples. I love how simple it is to use these kits and the reliability and reproducibility of the end materials obtained from these kits.

Heather Martinez

Associate Director, Global Strategic Marketing, Microbiome

Heather Martinez received her PhD in Biomedical Sciences from the University of California, San Diego in 2007 and has a scientific background in subjects including microbiome research, molecular biology, cell biology and protein biochemistry. She was Associate Director of Marketing at MO BIO Laboratories, Inc. which was acquired by QIAGEN in 2015. Currently, Dr. Martinez is responsible for strategic marketing for QIAGEN’s microbiome portfolio.

Your email address will not be published. Required fields are marked *